Nonstructural protein 14 (nsp14) (nsp14)

Nonstructural protein 14 (nsp14) is a critical bifunctional enzyme required for the replication and pathogenesis of the SARS-CoV-2 virus [1, 3, 6]. It consists of two functional domains: an N-terminal 3'-to-5' exoribonuclease (ExoN) and a C-terminal N7-guanine methyltransferase (N7-MTase) [3, 6]. The ExoN domain provides a proofreading function that excises misincorporated nucleotides during viral RNA synthesis, ensuring high genomic fidelity and enabling the virus to maintain its unusually large RNA genome [1, 3, 12]. This activity is also a major driver of resistance to nucleoside analog drugs like remdesivir and ribavirin, as nsp14 can remove these inhibitors from the growing RNA strand [1, 9]. The N7-MTase domain is responsible for methylating the viral mRNA cap, which is essential for efficient translation by host ribosomes and for masking the viral genome from detection by innate immune sensors such as RIG-I and MDA5 [4, 11, 14]. Furthermore, nsp14 modulates host cell signaling by activating pro-inflammatory pathways like NF-κB and MAPK, which can lead to the excessive cytokine production seen in severe COVID-19 cases [10, 11, 13]. As a therapeutic target, nsp14 inhibition offers a strategy to induce 'lethal mutagenesis' in the virus or to restore the efficacy of existing antivirals while simultaneously blocking viral immune evasion [1, 8, 14].

Other names

ExoNN7-MTase3'-to-5' exoribonucleaseGuanine-N7-methyltransferaseProofreading exonucleasensp14

Inhibition of the 3'-5' exoribonuclease domain to increase the viral mutation rate (lethal mutagenesis) and sensitize the virus to nucleoside analogs, or inhibition of the N7-methyltransferase domain to prevent viral mRNA capping, which reduces viral translation and enhances host immune detection of viral RNA.